S&P 500 Futures Climb In Premarket Trading; Neurocrine Biosciences, Equitable Holdings Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Neurocrine Biosciences Inc. (NBIX) was up 8.8% in
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 62.1%
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper Sandler
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper
Roivant Sciences Is Maintained at Overweight by Piper Sandler
Roivant Sciences Is Maintained at Overweight by Piper
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and adjusts the target price from $20 to $22.According to TipRanks data, the analyst has a success rate
Express News | Roivant Sciences Ltd : Piper Sandler Raises Target Price to $22 From $20
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview o
Express News | Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Roivant Sciences' (NASDAQ:ROIV) Performance Raises Some Questions
Even though Roivant Sciences Ltd. (NASDAQ:ROIV) posted strong earnings recently, the stock hasn't reacted in a large way. We decided to have a deeper look, and we believe that investors might be worr
Buy Rating Justified by Roivant Sciences' Growth Prospects and Strategic Pipeline Expansion
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
6 analysts have shared their evaluations of Roivant Sciences (NASDAQ:ROIV) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments, th
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Express News | HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Roivant Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 71.43% HC Wainwright & Co. $18 → $18 Reiterates Buy → Buy 04/22/2024 71.43% HC Wainwright & Co.
Express News | Roivant Sciences Ltd : Guggenheim Raises Target Price to $18 From $16
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Risinger Recommends 'Buy' for Roivant Sciences With Optimistic Brepocitinib Revenue Forecast and Increased Price Target
10-K: Annual report
Daily short sale tracking: American Airlines's short volume increased by 22 million, with a short sale ratio of 17%
American Airlines(AAL.US) ranked top of the list had the largest change in short volume (22.1 million shares), and the short volume ratio of Levi Strauss & Co.(LEVI.US) reached 48.04%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Express News | Roivant Sciences Ltd: Novaquest Agreement Amendment Provides for Elimination of Fixed Quarterly Payments Totaling $176.3 Mln